Combining Galantamine and Memantine in Multitargeted, New Chemical Entities Potentially Useful in Alzheimer’s Disease

PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT

Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 315,771 · see citing works

Gapped BLAST and PSI-BLAST: a new generation of protein database search programs

Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302 · see citing works

A new and rapid colorimetric determination of acetylcholinesterase activity

Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,221 · see citing works

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922 · see citing works

Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

Halgren, T. A. (1996) · Journal of Computational Chemistry · doi:10.1002/(sici)1096-987x(199604)17:5/6 · Cited by 5,321 · see citing works

Network pharmacology: the next paradigm in drug discovery

Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622 · see citing works

ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation

Abagyan, R., Totrov, M., & Kuznetsov, D. (1994) · Journal of Computational Chemistry · doi:10.1002/jcc.540150503 · Cited by 1,667 · see citing works

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644 · see citing works

Multi-target-Directed Ligands To Combat Neurodegenerative Diseases

Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152 · see citing works

Multi-target therapeutics: when the whole is greater than the sum of the parts

Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105 · see citing works

Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors

McGehee, D. S., Heath, M. J. S., Gelber, S., Devay, P., & Role, L. W. (1995) · Science · doi:10.1126/science.7569895 · Cited by 1,070 · see citing works

Alzheimer's disease: strategies for disease modification

Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,060 · see citing works

Protein database searches using compositionally adjusted substitution matrices

Altschul, S. F., Wootton, J. C., Gertz, E. M., Agarwala, R., Morgulis, A. O., Schäffer, A. A., & Yu, Y. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.04945.x · Cited by 1,058 · see citing works

Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond

Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909 · see citing works

Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potential

Mony, L., Kew, J. N. C., Gunthorpe, M. J., & Paoletti, P. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00304.x · Cited by 404 · see citing works

Memantine Preferentially Blocks Extrasynaptic over Synaptic NMDA Receptor Currents in Hippocampal Autapses

Xia, P., Chen, H.-S. V., Zhang, D., & Lipton, S. A. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2488-10.2010 · Cited by 380 · see citing works

Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors

Karakaş, E., Simorowski, N., & Furukawa, H. (2011) · Nature · doi:10.1038/nature10180 · Cited by 346 · see citing works

Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors

Samochocki, M., Höffle‐Maas, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., Radina, M., Zerlin, M., Ullmer, C., Pereira, E. F. R., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045773 · Cited by 345 · see citing works

Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase

Pang, Y., Quiram, P. A., Jelacic, T. M., Hong, F., & Brimijoin, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23646 · Cited by 344 · see citing works

Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II

Kryger, G., Harel, M., Giles, K., et al. (2000) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444900010659 · Cited by 312 · see citing works

3-(4-{[Benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) Inhibits Both Acetylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation: A Dual Function Lead for Alzheimer's Disease Therapy

Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., & Recanatini, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0340602 · Cited by 268 · see citing works

Multi-Target-Directed Drug Design Strategy: From a Dual Binding Site Acetylcholinesterase Inhibitor to a Trifunctional Compound against Alzheimer’s Disease

Bolognesi, M. L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., & Melchiorre, C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701225u · Cited by 262 · see citing works

Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

Piazzi, L., Cavalli, A., Colizzi, F., Belluti, F., Bartolini, M., Mancini, F., Recanatini, M., Andrisano, V., & Rampa, A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.100 · Cited by 215 · see citing works

Fragments, network biology and designing multiple ligands

Morphy, R., & Ranković, Z. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.006 · Cited by 204 · see citing works

Inhibition of Acetylcholinesterase, β-Amyloid Aggregation, and NMDA Receptors in Alzheimer’s Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush

Rosini, M., Simoni, E., Bartolini, M., Cavalli, A., Ceccarini, L., Pascu, N., McClymont, D. W., Tarozzi, A., Bolognesi, M. L., Minarini, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800577j · Cited by 186 · see citing works

Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence

Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182 · see citing works

Four-Dimensional Docking: A Fast and Accurate Account of Discrete Receptor Flexibility in Ligand Docking

Bottegoni, G., Kufareva, I., Totrov, M. M., & Abagyan, R. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8009958 · Cited by 181 · see citing works

A Small Molecule Targeting the Multifactorial Nature of Alzheimer's Disease

Cavalli, A., Bolognesi, M. L., Capsoni, S., Andrisano, V., Bartolini, M., Margotti, E., Cattaneo, A., Recanatini, M., & Melchiorre, C. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700256 · Cited by 180 · see citing works

Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?

Palmer, A. M., & Gershon, S. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.10.2165009 · Cited by 170 · see citing works

The Nicotinic Allosteric Potentiating Ligand Galantamine Facilitates Synaptic Transmission in the Mammalian Central Nervous System

Santos, M. D., Alkondon, M., Pereira, E. F. R., Aracava, Y., Eisenberg, H. M., Maelicke, A., & Albuquerque, E. X. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.5.1222 · Cited by 169 · see citing works

A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch

Small, G. W., & Dubois, B. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x233403 · Cited by 150 · see citing works

Bivalent β-Carbolines as Potential Multitarget Anti-Alzheimer Agents

Rook, Y. R. N., Schmidtke, K.-U., Gaube, F., Schepmann, D., Wünsch, B., Heilmann, J., Lehmann, J., & Winckler, T. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1000024 · Cited by 135 · see citing works

The Complex of a Bivalent Derivative of Galanthamine with Torpedo Acetylcholinesterase Displays Drastic Deformation of the Active-Site Gorge: Implications for Structure-Based Drug Design

Greenblatt, H. M., Guillou, C., Guénard, D., et al. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0466154 · Cited by 126 · see citing works

The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies

Chazot, P. L. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043456061 · Cited by 125 · see citing works

Heterodimeric Tacrine-Based Acetylcholinesterase Inhibitors: Investigating Ligand−Peripheral Site Interactions

Carlier, P. R., Chow, E. S. ‐., Han, Y., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990224w · Cited by 125 · see citing works

1‐Aminocyclopropane Carboxylic Acid: A Potent and Selective Ligand for the Glycine Modulatory Site of the N‐Methyl‐ d ‐Aspartate Receptor Complex

Marvizón, J. C. G., Lewin, A. H., & Skolnick, P. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb02554.x · Cited by 119 · see citing works

Memoquin: A Multi-Target–Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease

Bolognesi, M. L., Cavalli, A., & Melchiorre, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.042 · Cited by 117 · see citing works

The role of fragment-based and computational methods in polypharmacology

Bottegoni, G., Favia, A. D., Recanatini, M., & Cavalli, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.002 · Cited by 116 · see citing works

Combination Therapy for Alzheimerʼs Disease

Patel, L., & Grossberg, G. T. (2011) · Drugs & Aging · doi:10.2165/11591860-000000000-00000 · Cited by 93 · see citing works

Cholinesterase Inhibitors: Xanthostigmine Derivatives Blocking the Acetylcholinesterase-Induced β-Amyloid Aggregation

Belluti, F., Rampa, A., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Andrisano, V., Cavalli, A., Recanatini, M., & Valenti, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049515h · Cited by 87 · see citing works

Pharmacology of Acetylcholinesterase Inhibitors andN‐methyl‐ d ‐aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease

Geerts, H., & Grossberg, G. T. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006288734 · Cited by 85 · see citing works

A new method for ligand docking to flexible receptors by dual alanine scanning and refinement (SCARE)

Bottegoni, G., Kufareva, I., Totrov, M. M., & Abagyan, R. A. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9188-5 · Cited by 81 · see citing works

Reductive methylation of primary and secondary amines and amino acids by aqueous formaldehyde and zinc

da Silva, R. A., Estevam, I. H. S., & Bieber, L. W. (2007) · Tetrahedron Letters · doi:10.1016/j.tetlet.2007.08.092 · Cited by 65 · see citing works

Rationale for Combination Therapy With Galantamine and Memantine in Alzheimer's Disease

Grossberg, G. T., Edwards, K. R., & Zhao, Q. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006288735 · Cited by 64 · see citing works

Acyclic Nucleoside Analogues as Inhibitors ofPlasmodiumfalciparumdUTPase

Nguyen, C., Ruda, G. F., Schipani, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060126s · Cited by 57 · see citing works

Mechanism of Action of Galantamine on N-Methyl-d-Aspartate Receptors in Rat Cortical Neurons

Moriguchi, S., Marszalec, W., Zhao, X., Yeh, J. Z., & Narahashi, T. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067603 · Cited by 57 · see citing works

NR2B-Containing NMDA Receptors Expression and Their Relationship to Apoptosis in Hippocampus of Alzheimer’s Disease-Like Rats

Liu, Z., Lv, C., Zhao, W., Song, Y., Pei, D., & Xu, T. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0726-0 · Cited by 36 · see citing works

Low concentrations of neuroactive steroids alter kinetics of [3H]ifenprodil binding to the NMDA receptor in rat frontal cortex

Johansson, T., Frändberg, P., Nyberg, F., & Grevès, P. L. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706397 · Cited by 11 · see citing works

Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies

Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331 · see citing works

Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease

Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323 · see citing works

Combination Drug Therapy for the Management of Alzheimer’s Disease

Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217 · see citing works

From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology

Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179 · see citing works

Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease

Prati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110 · see citing works

Multi-Target Drug Candidates for Multifactorial Alzheimer’s Disease: AChE and NMDAR as Molecular Targets

Uddin, M. S., Al Mamun, A., Kabir, M. T., Ashraf, G. M., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02116-9 · Cited by 86 · see citing works

Galantamine potentiates the neuroprotective effect of memantine against<scp>NMDA</scp>‐induced excitotoxicity

Lopes, J. P., Tarozzo, G., Reggiani, A., Piomelli, D., & Cavalli, A. (2013) · Brain and Behavior · doi:10.1002/brb3.118 · Cited by 64 · see citing works

Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease

Marotta, G., Basagni, F., Rosini, M., & Minarini, A. (2020) · Molecules · doi:10.3390/molecules25174005 · Cited by 61 · see citing works

Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy

Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51 · see citing works

Perbandingan Efektivitas Penggunaan Donepezil dan Memantine Terhadap Perbaikan Fungsi Kognitif pada Penyakit Alzheimer

Alamri, K. N. H., Posangi, J., & Nangoy, E. (2021) · Jurnal Biomedik JBM · doi:10.35790/jbm.13.2.2021.31950 · Cited by 2 · see citing works

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil

Kano, O., Ito, H., Takazawa, T., et al. (2013) · DOAJ (DOAJ: Directory of Open Access Journals)

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis

Tan, C.-C., Yu, J.-T., Wang, H.-F., Tan, M.-S., Meng, X.-F., Wang, C., Jiang, T., Zhu, X.-C., & Tan, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132690 · Cited by 484 · see citing works

PNL3 RETROSPECTIVE COMPARATIVE ANALYSIS OF ANTIDEMENTIA MEDICATION PERSISTENCE PATTERNS AT 3 YEARS IN SPANISH ALZHEIMER DISEASE PATIENTS TREATED WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE

Sicras, A., Vergara, J., León, T., et al. (2005) · Value in Health · doi:10.1016/s1098-3015(10)67542-0 · Cited by 10 · see citing works

Drugs for cognitive loss and dementia.

Bazil, C. W., Crouse, E. L. B., Dalton, V. K., et al. (2007) · PubMed · Cited by 3 · see citing works